MA53164A - Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase - Google Patents

Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase

Info

Publication number
MA53164A
MA53164A MA053164A MA53164A MA53164A MA 53164 A MA53164 A MA 53164A MA 053164 A MA053164 A MA 053164A MA 53164 A MA53164 A MA 53164A MA 53164 A MA53164 A MA 53164A
Authority
MA
Morocco
Prior art keywords
rho
kinase inhibitors
amide derivatives
derivatives used
tyrosine amide
Prior art date
Application number
MA053164A
Other languages
English (en)
Inventor
Alessandro Accetta
Gurdip Bhalay
Anna Maria Capelli
Arnaud Jean Francois Auguste Cheguillaume
David Edward Clark
Christine Edwards
Fabio Rancati
Patrizia Tisselli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA53164A publication Critical patent/MA53164A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053164A 2018-07-16 2019-07-12 Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase MA53164A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18183733 2018-07-16

Publications (1)

Publication Number Publication Date
MA53164A true MA53164A (fr) 2021-05-26

Family

ID=62975943

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053164A MA53164A (fr) 2018-07-16 2019-07-12 Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase

Country Status (13)

Country Link
US (1) US20210284639A1 (fr)
EP (1) EP3823969A1 (fr)
JP (1) JP2021529819A (fr)
KR (1) KR20210032977A (fr)
CN (1) CN112752757B (fr)
AR (1) AR115766A1 (fr)
AU (1) AU2019304472A1 (fr)
BR (1) BR112021000101A2 (fr)
CA (1) CA3104955A1 (fr)
MA (1) MA53164A (fr)
MX (1) MX2021000270A (fr)
TW (1) TW202019923A (fr)
WO (1) WO2020016129A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230121812A (ko) 2020-12-15 2023-08-21 키에시 파르마슈티시 엣스. 피. 에이. Rho-키나아제 억제제로서 다이하이드로퓨로피리딘 유도체
KR20230121811A (ko) 2020-12-15 2023-08-21 키에시 파르마슈티시 엣스. 피. 에이. Rho-키나아제 억제제로서 다이하이드로퓨로피리딘 유도체
MX2023005867A (es) 2020-12-15 2023-06-05 Chiesi Farm Spa Derivados de dihidrofuropiridina como inhibidores de la cinasa rho.
WO2023110700A1 (fr) 2021-12-13 2023-06-22 Chiesi Farmaceutici S.P.A. Dérivés de dihydrofuropyridine utilisés comme inhibiteurs de la rho-kinase

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003278088A1 (en) 2002-10-28 2004-05-25 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
WO2006009889A1 (fr) 2004-06-17 2006-01-26 Smithkline Beecham Corporation Inhibiteurs novateurs de protéines rho-kinases
WO2007026920A2 (fr) * 2005-09-02 2007-03-08 Astellas Pharma Inc. Nouveaux composes
CA2709918A1 (fr) 2007-12-21 2009-06-25 The Scripps Research Institute Benzopyranes et analogues utilises comme inhibiteurs de la rho kinase
EP2100598A1 (fr) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
CN102159547A (zh) 2008-09-18 2011-08-17 安斯泰来制药株式会社 杂环甲酰胺化合物
MA34373B1 (fr) 2010-07-14 2013-07-03 Novartis Ag Composés hétérocycliques agonistes du récepteur ip
WO2012168349A1 (fr) * 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Composés ayant une activité antagoniste des récepteurs muscariniques et une activité agoniste des récepteurs adrénergique bêta-2
SI2951172T1 (sl) 2013-01-29 2017-08-31 Redx Pharma Plc Piridin derivati kot inhibitorji mehkih kamnov
TWI800498B (zh) 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
CA3047212A1 (fr) * 2017-01-30 2018-08-02 Chiesi Farmaceutici S.P.A. Derives de tyrosine amide utilises en tant qu'inhibiteurs de la rho-kinase

Also Published As

Publication number Publication date
EP3823969A1 (fr) 2021-05-26
AR115766A1 (es) 2021-02-24
MX2021000270A (es) 2021-03-26
WO2020016129A1 (fr) 2020-01-23
KR20210032977A (ko) 2021-03-25
CA3104955A1 (fr) 2020-01-23
JP2021529819A (ja) 2021-11-04
US20210284639A1 (en) 2021-09-16
TW202019923A (zh) 2020-06-01
AU2019304472A1 (en) 2021-02-11
CN112752757A (zh) 2021-05-04
CN112752757B (zh) 2024-01-12
BR112021000101A2 (pt) 2021-03-30

Similar Documents

Publication Publication Date Title
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54452A (fr) Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA51610A (fr) Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
EP3601239A4 (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
EP3768671A4 (fr) Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5
EP3941525A4 (fr) Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA54157A (fr) Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA50439A (fr) Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3
MA50013A (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
EP4043450A4 (fr) Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac
MA53164A (fr) Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6